{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+sitagliptin&page=2", "query": { "intervention": "Placebo to match sitagliptin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+sitagliptin&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+match+sitagliptin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-08T06:18:13.855Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01552694", "title": "Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Inflammation", "Macrophage Infiltration", "Cardiovascular Disease" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 38, "start_date": "2012-10", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-05-08", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01552694" }, { "nct_id": "NCT01829464", "title": "TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-875", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2013-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829464" }, { "nct_id": "NCT01106690", "title": "The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 344, "start_date": "2010-06", "completion_date": "2012-07", "has_results": true, "last_update_posted_date": "2013-07-15", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 41, "location_summary": "Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106690" }, { "nct_id": "NCT01834274", "title": "Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Fasiglifam (TAK-875)", "type": "DRUG" }, { "name": "Fasiglifam (TAK-875) Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2013-06", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 44, "location_summary": "Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01834274" }, { "nct_id": "NCT01098539", "title": "A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "albiglutide", "type": "BIOLOGICAL" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 507, "start_date": "2010-05", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-02-28", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 97 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Toney", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098539" }, { "nct_id": "NCT03101930", "title": "Cardiovascular Effects of GLP-1 Receptor Activation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obesity", "PreDiabetes" ], "interventions": [ { "name": "Liraglutide", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "hypocaloric diet", "type": "OTHER" }, { "name": "Placebos", "type": "DRUG" }, { "name": "Exendin (9-39)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 329, "start_date": "2017-05-01", "completion_date": "2021-06-24", "has_results": true, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03101930" }, { "nct_id": "NCT01119846", "title": "A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK1292263", "type": "DRUG" }, { "name": "GSK1292263 matching placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": "2009-06-05", "completion_date": "2010-03-19", "has_results": true, "last_update_posted_date": "2018-01-17", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01119846" }, { "nct_id": "NCT01413542", "title": "Pharmacogenetics of Ace Inhibitor-Associated Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypertension", "Diabetes Type 2" ], "interventions": [ { "name": "Sitagliptin (DPP4 inhibitor)", "type": "DRUG" }, { "name": "Substance P,", "type": "DRUG" }, { "name": "bradykinin", "type": "DRUG" }, { "name": "enalaprilat (ACE inhibitor)", "type": "DRUG" }, { "name": "Glucagon-like peptide 1", "type": "DRUG" }, { "name": "brain natriuretic peptide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2011-11", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413542" }, { "nct_id": "NCT03646721", "title": "A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "DA-1241", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dong-A ST Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 108, "start_date": "2018-08-29", "completion_date": "2020-05-07", "has_results": false, "last_update_posted_date": "2021-02-11", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 4, "location_summary": "Chula Vista, California • Miami, Florida • High Point, North Carolina + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" }, { "city": "Renton", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03646721" }, { "nct_id": "NCT01155284", "title": "Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Sitagliptin and Lansoprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanford Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "11 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "11 Years to 45 Years" }, "enrollment_count": 70, "start_date": "2010-08", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-10-08T06:18:13.855Z", "location_count": 3, "location_summary": "San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01155284" } ] }